Goldman Sachs Group Inc. Acquires Shares of 75,146 Kamada Ltd. $KMDA

Key Points

• Goldman Sachs Group Inc. acquired 75,146 shares of Kamada Ltd., valued at approximately $497,000, representing around 0.13% ownership in the company.
• Other institutional investors, including NewEdge Advisors LLC and Huntleigh Advisors Inc., also increased their stakes in Kamada during the first quarter, contributing to a total institutional ownership of 20.38%.
• Kamada reported earnings of $0.13 per share for the last quarter, surpassing analysts' expectations, but its revenue of $44.75 million fell short of the forecast of $158.59 million.

Goldman Sachs Group Inc. bought a new position in Kamada Ltd. (NASDAQ:KMDA - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 75,146 shares of the biotechnology company's stock, valued at approximately $497,000. Goldman Sachs Group Inc. owned approximately 0.13% of Kamada as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the business. Trexquant Investment LP bought a new stake in shares of Kamada during the 1st quarter worth $82,000. NewEdge Advisors LLC raised its stake in Kamada by 119.9% during the 1st quarter. NewEdge Advisors LLC now owns 51,661 shares of the biotechnology company's stock valued at $341,000 after purchasing an additional 28,165 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in Kamada during the 1st quarter valued at $206,000. Jane Street Group LLC acquired a new position in Kamada during the 1st quarter valued at $582,000. Finally, Huntleigh Advisors Inc. acquired a new position in Kamada during the 1st quarter valued at $863,000. 20.38% of the stock is owned by institutional investors.

Kamada Price Performance

NASDAQ:KMDA opened at $6.69 on Friday. The stock has a market cap of $384.74 million, a P/E ratio of 19.68, a PEG ratio of 0.73 and a beta of 0.89. Kamada Ltd. has a one year low of $5.17 and a one year high of $9.15. The company has a fifty day moving average price of $7.18 and a 200 day moving average price of $7.00.

Kamada (NASDAQ:KMDA - Get Free Report) last announced its quarterly earnings data on Wednesday, August 13th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.09 by $0.04. Kamada had a net margin of 11.22% and a return on equity of 7.41%. The company had revenue of $44.75 million during the quarter, compared to analysts' expectations of $158.59 million. Kamada has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that Kamada Ltd. will post 0.23 EPS for the current year.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.

Want to see what other hedge funds are holding KMDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kamada Ltd. (NASDAQ:KMDA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.